ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 16 (1) 225 -231     DOI: 10.1677/ERC-08-0152
Copyright © 2009 by the Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ERC-08-0152v1
16/1/225    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faggiano, A
Right arrow Articles by Ferolla, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faggiano, A
Right arrow Articles by Ferolla, P

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

A Faggiano, F Grimaldi1, L Pezzullo2, M G Chiofalo2, C Caracò3, N Mozzillo2, G Angeletti4, F Santeusanio4, G Lombardi, A Colao, N Avenia5 and P Ferolla4

Department of Molecular and Clinical Endocrinology and Oncology, ‘Federico II’ University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy1 Department of Endocrinology, ‘S. Maria della Misericordia’ Hospital, Udine, Italy2 Department of Surgery, National Cancer Institute, ‘Fondazione G. Pascale’, Naples, Italy3 Department of Nuclear Medicine, National Cancer Institute, ‘Fondazione G. Pascale’, Naples, Italy4 Department of Internal Medicine and Endocrine Sciences, University of Perugia, Perugia, Italy5 Department of Endocrine Surgery, University of Perugia, Perugia, Italy

(Correspondence should be addressed to A Faggiano; Email: afaggian{at}unina.it)

In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)–positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG–PET positivity was significantly associated with calcitonin serum concentrations >400 pg/ml and Ki-67 score >2.0% (P<0.05), while SRS positivity was associated with calcitonin serum concentrations >800 pg/ml (P<0.05). SRS positivity significantly correlated with tumor appearance at CIT (P<0.01), while FDG–PET was positive in nine CIT-negative patients. The secretive and proliferative tumor profile may guide the choice of the imaging technique to use in the follow-up of patients with MTC. A Ki-67 score >2.0% suggests to perform a FDG–PET in addition to conventional imaging. Calcitonin secretion predicts both FDG–PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Society for Endocrinology.